Dermata Therapeutics (DRMA) Stock Price, News & Analysis

Company Overview

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques. This integrated platform enables the identification and optimization of both topical and oral small molecules that modulate key intracellular signaling pathways involved in skin inflammation.

Headquartered in Cambridge, Massachusetts, Dermata collaborates with academic institutions and contract research organizations across the United States and Europe to conduct translational studies and clinical trials. The company’s network of clinical sites supports the efficient advancement of its pipeline from preclinical research through clinical development.

Dermata’s management team brings together expertise in pharmaceutical research and development, regulatory affairs and dermatology commercialization. With a focus on addressing unmet needs in skin health, the company aims to deliver best-in-class therapies that improve outcomes and quality of life for patients living with inflammatory skin diseases.

Key Stats

• Today's Range: $1.50 to $1.72
• 50-Day Range: $1.08 to $1.72
• 52-Week Range: $0.95 to $6.22
• Volume: 194,563 shs
• Average Volume: 2.17 million shs
• Market Capitalization: $6.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Dermata Therapeutics Stock Analysis - MarketRank™

Dermata Therapeutics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Dermata Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Dermata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dermata Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dermata Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dermata Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.68% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently increased by 622.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dermata Therapeutics does not currently pay a dividend.

Dividend Growth

Dermata Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Dermata Therapeutics this week, compared to 1 article on an average week.

Search Interest

1 people have searched for DRMA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.90% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

8.67% of the stock of Dermata Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: Personal Care Products
• Sub-Industry: Personal Care Products
• Current Symbol: NASDAQ:DRMA
• CIK: 1853816
• Web: www.dermatarx.com
• Phone: 858-800-2543
• Fax: N/A
• Employees: 8
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($4.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -166.66%
• Return on Assets: -130.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.81
• Quick Ratio: 2.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.87 per share
• Price / Book: 1.98

Miscellaneous

• Outstanding Shares: 4,020,000
• Free Float: 3,141,000
• Market Cap: $6.91 million
• Optionable: Not Optionable
• Beta: 0.66